Don’t miss the latest developments in business and finance.

Pharma stocks spurt after India lifts curbs on exports

Image
Capital Market
Last Updated : Apr 07 2020 | 2:50 PM IST

Pharma stocks were in demand after the government allowed export of select active pharmaceutical ingredients (API), including antibiotics, vitamins and hormones as well as their formulations, that were placed under restriction early last month.

The Nifty Pharma index jumped 9.84% to 8,085.80, extending its winning run to second consecutive session. The index has surged 15.07% in just two trading sessions. The index outperformed all other sectoral indices on the NSE.

Cadila Healthcare (up 14.4%), Dr. Reddy's Laboratories (up 12.4%), Aurobindo Pharma (up 12.11%), Cipla (up 10.96%), Sun Pharmaceutical Inds (up 10.11%), Divi's Laboratories (up 10%), Glenmark Pharmaceuticals (up 8.28%), Biocon (up 7.1%) and Lupin (up 6.74%) were top gainers in pharmaceutical space.

The government had imposed the restrictions last month as the coronavirus outbreak disrupted global supply chains.

Further, India will also supply paracetamol and hydroxychloroquine in "appropriate quantities" to all neighbouring countries and nations who badly need the medicines in wake of coronavirus crisis. The export of hydroxychloroquine and paracetamol will be now taken up on a 'case-to-case basis', depending on the availability of stock after meeting domestic requirements, reports suggested.

Hydroxychloroquine tablet is used to prevent and treat malaria, lupus and rheumatoid arthritis, among other ailments, while paracetamol is used to treat pain and fever. The United States has been touting hydroxychloroquine as a potential drug that can cure Coronavirus.

Powered by Capital Market - Live News

Also Read

First Published: Apr 07 2020 | 2:02 PM IST

Next Story